Drug Profile
EMD 534085
Alternative Names: EMD534085Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck Serono
- Class Antineoplastics
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies in France (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in France (IV, Infusion)
- 21 Apr 2010 Efficacy, adverse events, and pharmacokinetics data from a phase I trial in cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)